None listed
Conditions
Interventions
None listed
Sponsors
Keimyung University Dongsan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: •Men or women aged = 19 years, <80 years •Hemodynamically stable nonvalvular AF or atrial flutter •VKA or NOAC-naïve or untreated within 1 month prior to sign the informed consent •LAA thrombus documented by TEE up to 72 hours prior to start of study medication •A person who understands the written description of the research method and has completed the written consent form
Exclusion criteria
Exclusion criteria: •Severe, disabling stroke (modified Rankin score of 4-5, inclusive) within 3 months or any stroke within 14 days before the start of study drug •Acute thromboembolic events or thrombosis (venous/arterial) within the last 14 days prior to study inclusion •Acute myocardial infarction within the last 14 days prior to study inclusion •Cardiac-related criteria: Previous intracardiac thrombus, Free-floating ball thrombus, Intracardiac tumor, known left ventricular or aortic thrombus •Active bleeding or high risk for bleeding contraindicating anticoagulant therapy i. Current history or history of hemorrhage or coagulation disorders ii. Thrombocytopenia iii. Pregnant patient •Patients who can not follow up after medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of subjects with complete resolution of LAA thrombi | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment responses of thrombi: Number of participants with resolved, reduced, unchanged, enlarged thrombi or newly appeared thrombi;The percentage of subjects who experienced ischemic stroke;The percentage of subjects who experienced bleeding event | — |
Countries
Korea, Republic of
Contacts
Public ContactSeongwook Han
Keimyung University Dongsan Medical Center
Outcome results
None listed